House committee probes Bristol, Merck, AbbVie over China trials

Regulation
โดย Seeking Alpha·Read original
Summary · why it matters

The House Select Committee on China has opened investigations into Bristol Myers Squibb, Merck, Pfizer, and AbbVie over the companies' clinical trials at Chinese military sites or hospitals. Chair John Moolenaar wrote to Bristol CEO Chris Boerner that the drugmaker sponsored trials at Chinese military hospitals and in Xinjiang, which he called the epicenter of the CCP's genocide targeting Uyghurs and other minorities. Moolenaar expressed a more positive sentiment to Pfizer CEO Albert Bourla, commending Pfizer's decision to no longer sponsor trials in Xinjiang and at PRC military hospitals, and seeking more details on the company's due diligence and its partnerships with Chinese biotech firms.

Impact on stocks 5

Biotech & Genomic Medicine▼ · 4 stocks
AbbVie Inc
ABBV
▼ NegativeRegulationrelevance

House committee probes AbbVie over clinical trials at Chinese military sites/hospitals.

Bristol-Myers Squibb Company
BMY
▼ NegativeRegulationrelevance

House committee probes Bristol Myers Squibb over clinical trials at Chinese military hospitals and in Xinjiang.

Merck & Company Inc
MRK
▼ NegativeRegulationrelevance

House committee probes Merck over clinical trials at Chinese military sites/hospitals.

Pfizer Inc
PFE
± MixedRegulationrelevance

Pfizer commended for ending Xinjiang/military trials but still probed for due diligence and partnerships.

Critical Materials & Supply Chain▲ · 1 stocks
© 2026 MarketDXNews